Terbinafine

Terbinafine is a synthetic allylamine antifungal with the molecular formula C21H25N, a white crystalline solid that dissolves readily in organic solvents but only sparingly in water. It was developed in the late 1980s and reached the market around 1991 in Europe, gaining approval in the United States in 1996; after patents expired it became a widely used generic. The drug is given both by mouth, where it concentrates in skin, nails, and fatty tissue, and applied to the skin as a cream, gel, or spray.

Its main use is against dermatophytes, the mold-like fungi that infect keratin-rich tissue. Oral terbinafine is a first-line treatment for onychomycosis, fungal infection of the nails, and for widespread or stubborn ringworm, the tinea infections of the body, groin, feet, and scalp; topical forms treat more limited athlete's foot, jock itch, and related skin infections, and the drug also has activity in pityriasis versicolor ^[2]. Correct identification of the infecting organism matters, because some non-dermatophyte molds respond poorly to terbinafine and call for different agents ^[2].

Although terbinafine is highly active against typical dermatophytes, resistance is an emerging concern. The first confirmed case of resistant Trichophyton rubrum was reported in a nail-infection patient who failed oral therapy, and the resistant isolates were cross-resistant to other squalene epoxidase inhibitors, pointing to a target-specific mechanism ^[3]. Later work traced such resistance to point mutations in the fungal squalene epoxidase gene, including amino-acid substitutions that weaken drug binding, and treatment guidance now suggests switching to azole antifungals when terbinafine fails ^[1][2].

Terbinafine is generally well tolerated but calls for attention to the liver: rare but serious hepatotoxicity has been reported, so clinicians typically avoid it in active liver disease and may check liver enzymes during longer oral courses. A distinctive adverse effect is disturbance or temporary loss of taste and smell, which usually resolves after the drug is stopped but can rarely persist. Other reported effects include gastrointestinal upset, headache, and skin reactions. The drug is an established prescription and, for some topical products, over-the-counter medicine used under the usual antifungal precautions.

Terbinafine tablets are prescription only, while the cream is often available over the counter. The tablets are generally well tolerated but can cause stomach upset, headache, rash and a change or loss of taste that can linger. Rarely they cause liver injury, so liver enzymes are often checked, and very rarely serious skin reactions or a lupus like flare can occur. Because it inhibits the CYP2D6 enzyme, it can raise levels of certain antidepressants, some beta blockers and other drugs. It is avoided in active or chronic liver disease.

Terbinafine is a potent inhibitor of CYP2D6, and this is the interaction worth knowing. In healthy volunteers with normal CYP2D6 activity it raised desipramine peak concentrations twofold and total exposure fivefold, effectively converting extensive metabolizers into poor metabolizers. The same applies to other CYP2D6 substrates: nortriptyline and related tricyclics, metoprolol, propafenone, flecainide, perphenazine and risperidone. Terbinafine concentrates in skin and fat with a terminal half-life measured in weeks, so the inhibition outlasts the course; the desipramine effect was still measurable four weeks after stopping. Tamoxifen depends on CYP2D6 to form its active metabolite endoxifen, so reduced activation follows on mechanism, though direct clinical data are thin.

Terbinafine's own levels move as well. Rifampin roughly doubles its clearance and cimetidine reduces clearance by about a third. Effects on caffeine metabolism through CYP1A2 exist but are modest.

Checking a whole stack? Run it through interactions + stacks.

Terbinafine was discovered by the Swiss pharmaceutical company Sandoz (now part of Novartis) in the early 1980s, emerging from a research program on the allylamine class of antifungals that had begun with the related compound naftifine. Chemists optimized the allylamine scaffold to improve potency and oral bioavailability, arriving at terbinafine as the lead candidate. It first reached the market in the early 1990s, initially as a topical cream and subsequently as the oral tablet marketed under the brand name Lamisil.

The oral formulation proved a milestone for dermatology because it accumulated in nail and skin keratin and offered high cure rates for onychomycosis, a notoriously difficult infection, with treatment courses far shorter than the older agent griseofulvin. Terbinafine has since become a first-line therapy for dermatophyte infections worldwide and appears in standard treatment guidelines. Its patents have long expired, and it is now widely available as an inexpensive generic.

Terbinafine enjoys a strong reputation as one of the most effective oral treatments for fungal nail and skin infections, frequently cited as the benchmark against which newer antifungals are measured. Clinicians value its fungicidal action, which destroys the organism rather than merely halting its growth, and its ability to concentrate in keratin means the drug keeps working in the nail for weeks after a course ends.

It is generally well tolerated, and because it does not depend on the fungal cytochrome enzymes that azoles inhibit, it carries a somewhat different and often more favorable interaction profile. Honesty requires noting its limits: rare cases of liver injury and taste disturbance are recognized, periodic monitoring is advised for longer oral courses, and reinfection or resistance can occur, particularly with certain dermatophyte strains now spreading in some regions. Even so, its combination of high efficacy, low cost, and decades of clinical experience keeps it a trusted mainstay.